Over the last year Novo shares continued to rise due to strong sales growth of its GLP-1 drugs ... from their AI tools, leaving potential for further acceleration in revenue growth in future years.

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

The 13 states where Medicaid covers GLP-1 drugs for obesity are California, Kansas, Minnesota, Wisconsin, Michigan, ...

GLP-1 receptor agonists, like Wegovy and Ozempic, have taken center stage in obesity and diabetes treatment ... Food itself is one of the best therapeutic tools for long-term health — and ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Among those states that don’t cover the ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Current GLP-1-based obesity medications ... from Reset Health for the management of obesity and type 2 diabetes, offering personalised car ...